Diabetes and Infectious Diseases with a Focus on Melioidosis.
Journal
Current microbiology
ISSN: 1432-0991
Titre abrégé: Curr Microbiol
Pays: United States
ID NLM: 7808448
Informations de publication
Date de publication:
04 Jun 2024
04 Jun 2024
Historique:
received:
12
01
2024
accepted:
19
05
2024
medline:
4
6
2024
pubmed:
4
6
2024
entrez:
4
6
2024
Statut:
epublish
Résumé
Diabetes mellitus (DM) leads to impaired innate and adaptive immune responses. This renders individuals with DM highly susceptible to microbial infections such as COVID-19, tuberculosis and melioidosis. Melioidosis is a tropical disease caused by the bacterial pathogen Burkholderia pseudomallei, where diabetes is consistently reported as the most significant risk factor associated with the disease. Type-2 diabetes is observed in 39% of melioidosis patients where the risk of infection is 13-fold higher than non-diabetic individuals. B. pseudomallei is found in the environment and is an opportunistic pathogen in humans, often exhibiting severe clinical manifestations in immunocompromised patients. The pathophysiology of diabetes significantly affects the host immune responses that play a critical role in fighting the infection, such as leukocyte and neutrophil impairment, macrophage and monocyte inhibition and natural killer cell dysfunction. These defects result in delayed recruitment as well as activation of immune cells to target the invading B. pseudomallei. This provides an advantage for the pathogen to survive and adapt within the immunocompromised diabetic patients. Nevertheless, knowledge gaps on diabetes-infectious disease comorbidity, in particular, melioidosis-diabetes comorbidity, need to be filled to fully understand the dysfunctional host immune responses and adaptation of the pathogen under diabetic conditions to guide therapeutic options.
Identifiants
pubmed: 38833191
doi: 10.1007/s00284-024-03748-z
pii: 10.1007/s00284-024-03748-z
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
208Subventions
Organisme : Kementerian Sains, Teknologi dan Inovasi
ID : FRGS/1/2021/STG02/UKM/01/1
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Tan SY, Mei Wong JL, Sim YJ, Wong SS, Mohamed Elhassan SA, Tan SH, Ling Lim GP, Rong Tay NW, Annan NC, Bhattamisra SK, Candasamy M (2019) Type 1 and 2 diabetes mellitus: a review on current treatment approach and gene therapy as potential intervention. Diabetes Metab Syndr 13(1):364–372. https://doi.org/10.1016/j.dsx.2018.10.008
doi: 10.1016/j.dsx.2018.10.008
pubmed: 30641727
Kahaly GJ, Hansen MP (2016) Type 1 diabetes associated autoimmunity. Autoimmun Rev 15(7):644–648. https://doi.org/10.1016/j.autrev.2016.02.017
doi: 10.1016/j.autrev.2016.02.017
pubmed: 26903475
Muoio DM, Newgard CB (2008) Mechanisms of disease: Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 9(3):193–205. https://doi.org/10.1038/nrm2327
doi: 10.1038/nrm2327
pubmed: 18200017
Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H, Martin C (2020) Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci 21(17):6275. https://doi.org/10.3390/2Fijms21176275
doi: 10.3390/2Fijms21176275
pubmed: 32872570
pmcid: 7503727
Global Burden of Disease Collaborative Network (2020) Global Burden of Disease Study 2019 Results. https://vizhub.healthdata.org/gbd-results/ . Accessed 1 Apr 2024
Casqueiro J, Casqueiro J, Alves C (2012) Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocrinol Metab 16(1):27–36. https://doi.org/10.4103/2F2230-8210.94253
doi: 10.4103/2F2230-8210.94253
Chávez-Reyes J, Escárcega-González CE, Chavira-Suárez E, León-Buitimea A, Vázquez-León P, Morones-Ramírez JR, Villalón CM, Quintanar-Stephano A, Marichal-Cancino BA (2021) Susceptibility for some infectious diseases in patients with diabetes: the key role of glycemia. Front Public Health 9:1–18. https://doi.org/10.3389/fpubh.2021.559595
doi: 10.3389/fpubh.2021.559595
Katz M, Smith S, Conway L (2018) Sinha A (2018) Melioidosis in a patient with type 1 diabetes mellitus on an insulin pump. Endocrinol Diabetes Metab Case Rep 1:1–3. https://doi.org/10.1530/EDM-18-0062
doi: 10.1530/EDM-18-0062
Baikunje N, Gangaramajalu S, Hosmane GB (2021) Melioidosis: A fulminant infection in a patient with uncontrolled diabetes. J Health Allied Sci NU 11(1):50–53. https://doi.org/10.1055/s-0040-1721232
doi: 10.1055/s-0040-1721232
Gulati U, Nanduri AC, Juneja P, Kaufman D, Elrod MG, Kolton CB, Gee JE, Garafalo K, Blaney DD (2022) Case report: a fatal case of latent melioidosis activated by COVID-19. Am J Trop Med Hyg 106(4):1170–1172. https://doi.org/10.4269/ajtmh.21-0689
doi: 10.4269/ajtmh.21-0689
pubmed: 35114640
pmcid: 8991333
Currie BJ, Ward L, Cheng AC (2010) The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis 4(11):e900. https://doi.org/10.1371/journal.pntd.0000900
doi: 10.1371/journal.pntd.0000900
pubmed: 21152057
pmcid: 2994918
Duangurai T, Indrawattana N, Pumirat P (2018) Burkholderia pseudomallei adaptation for survival in stressful conditions. Biomed Res Int 2018:1–11. https://doi.org/10.1155/2018/3039106
doi: 10.1155/2018/3039106
Kaewpan A, Duangurai T, Rungruengkitkun A, Muangkaew W, Kanjanapruthipong T, Jitprasutwit N, Ampawong S, Sukphopetch P, Chantratita N, Pumirat IdP (2022) Burkholderia pseudomallei pathogenesis in human skin fibroblasts: a Bsa type III secretion system is involved in the invasion, multinucleated giant cell formation, and cellular damage. PLoS ONE 17(2):1–20. https://doi.org/10.1371/journal.pone.0261961
doi: 10.1371/journal.pone.0261961
Nathan S, Chieng S, Kingsley PV, Mohan A, Podin Y, Ooi MH, Mariappan V, Vellasamy KM, Vadivelu J, Daim S, How SH (2018) Melioidosis in Malaysia: incidence, clinical challenges, and advances in understanding pathogenesis. Trop Med Infect Dis 3(1):1–19. https://doi.org/10.3390/tropicalmed3010025
doi: 10.3390/tropicalmed3010025
Beard DK, Subramanian S, Abendroth J, Dranow DM, Edwards TE, Myler PJ, Asojo OA (2022) Crystal structure of betaine aldehyde dehydrogenase from Burkholderia pseudomallei. Acta Crystallogr F Struct Biol Commun 78(2):45–51. https://doi.org/10.1107/S2053230X21013455
doi: 10.1107/S2053230X21013455
pubmed: 35102892
pmcid: 8805214
GBD (2021) Diabetes Collaborators (2023) Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021. Lancet 402(10397):203–234. https://doi.org/10.1016/S0140-6736(23)01301-6
doi: 10.1016/S0140-6736(23)01301-6
Safiri S, Karamzad N, Kaufman JS, Bell AW, Nejadghaderi SA, Sullman MJM, Moradi-Lakeh M, Collins G, Kolahi AA (2022) Prevalence, deaths and disability-adjusted-life-years (DALYs) due to type 2 diabetes and its attributable risk factors in 204 countries and territories, 1990–2019: results from the global burden of disease study 2019. Front Endocrinol 13:1–14. https://doi.org/10.3389/fendo.2022.838027
doi: 10.3389/fendo.2022.838027
Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al KJ (2020) Epidemiology of type 2 diabetes—global burden of disease and forecasted trends. J Epidemiol Glob Health 10(1):107–111. https://doi.org/10.2991/jegh.k.191028.001
doi: 10.2991/jegh.k.191028.001
pubmed: 32175717
pmcid: 7310804
World Health Organization (n.d.) Diabetes. https://www.who.int/news-room/fact-sheets/detail/diabetes . Accessed 1 Apr 2024
Dunachie S, Chamnan P (2019) The double burden of diabetes and global infection in low and middle-income countries. Trans R Soc Trop Med Hyg 113(2):56–64. https://doi.org/10.1093/trstmh/try124
doi: 10.1093/trstmh/try124
pubmed: 30517697
Hodgson K, Morris J, Bridson T, Govan B, Rush C, Ketheesan N (2015) Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. Immunology 144(2):171–185. https://doi.org/10.1111/imm.12394
doi: 10.1111/imm.12394
pubmed: 25262977
pmcid: 4298412
Dowey R, Iqbal A, Heller SR, Sabroe I, Prince LR (2021) A bittersweet response to infection in diabetes; targeting neutrophils to modify inflammation and improve host immunity. Front Immunol 12:1–21. https://doi.org/10.3389/fimmu.2021.678771
doi: 10.3389/fimmu.2021.678771
Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R (2020) Type 2 diabetes and its impact on the immune system. Curr Diabetes Rev 16(5):442–449. https://doi.org/10.2174/1573399815666191024085838
doi: 10.2174/1573399815666191024085838
pubmed: 31657690
pmcid: 7475801
Stew SS, Martinez PJ, Schlesinger LS, Restrepo BI (2013) Differential expression of monocyte surface markers among TB patients with diabetes co-morbidity. Tuberculosis 93:78–82. https://doi.org/10.1016/S1472-9792(13)70015-5
doi: 10.1016/S1472-9792(13)70015-5
Pavlou S, Lindsay J, Ingram R, Xu H, Chen M (2018) Sustained high glucose exposure sensitizes macrophage responses to cytokine stimuli but reduces their phagocytic activity. BMC Immunol 19(1):24. https://doi.org/10.1186/s12865-018-0261-0
doi: 10.1186/s12865-018-0261-0
pubmed: 29996768
pmcid: 6042333
Toniolo A, Cassani G, Puggioni A, Rossi A, Colombo A, Onodera T, Ferrannini E (2019) The diabetes pandemic and associated infections: Suggestions for clinical microbiology. Rev Med Microbio 30(1):1–17. https://doi.org/10.1097/MRM.0000000000000155
doi: 10.1097/MRM.0000000000000155
Davis KE, Prasad C, Vijayagopal P, Juma S, Imrhan V (2016) Advanced glycation end products, inflammation, and chronic metabolic diseases: links in a chain? Crit Rev Food Sci Nutr 56(6):989–998. https://doi.org/10.1080/10408398.2012.744738
doi: 10.1080/10408398.2012.744738
pubmed: 25259686
Kim JH, Park K, Lee SB, Kang S, Park JS, Ahn CW, Nam JS (2019) Relationship between natural killer cell activity and glucose control in patients with type 2 diabetes and prediabetes. J Diabetes Investig 10(5):1223–1228. https://doi.org/10.1111/jdi.130022
doi: 10.1111/jdi.130022
pubmed: 30618112
pmcid: 6717814
Kim DY, Lee JK (2022) Type 1 and 2 diabetes are associated with reduced natural killer cell cytotoxicity. Cell Immunol. https://doi.org/10.1016/j.cellimm.2022.104578
doi: 10.1016/j.cellimm.2022.104578
pubmed: 35012755
Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11(2):98–107. https://doi.org/10.1038/nri2925
doi: 10.1038/nri2925
pubmed: 21233852
Egede LE, Hull BJ, Williams JS, Cowie CC, Casagranade SS, Menke A et al (2018) Diabetes in America, 3rd edn. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, pp 1–25
Carey IM, Critchley JA, Chaudhry UAR, DeWilde S, Limb ES, Cook DG, Whincup PH, Harris T (2023) Evaluating ethnic variations in the risk of infections in people with prediabetes and type 2 diabetes: a matched cohort study. Diabetes Care 46(6):1209–1217. https://doi.org/10.2337/dc22-2394
doi: 10.2337/dc22-2394
pubmed: 37043827
pmcid: 10234749
Knoop J, Gavrisan A, Kuehn D, Reinhardt J, Heinrich M, Hippich M, Eugster A, Ockert C, Ziegler AG, Bonifacio E (2018) GM-CSF producing autoreactive CD4+ T cells in type 1 diabetes. Clin Immunol 188:23–30. https://doi.org/10.1016/j.clim.2017.12.002
doi: 10.1016/j.clim.2017.12.002
pubmed: 29229565
Kumar NP, Sridhar R, Nair D, Banurekha VV, Nutman TB, Babu S (2014) Type 2 diabetes mellitus is associated with altered CD8+ T and natural killer cell function in pulmonary tuberculosis. Immunology 144(4):677–686. https://doi.org/10.1111/imm.12421
doi: 10.1111/imm.12421
Erener S (2020) Diabetes, infection risk and COVID-19. Mol Metab 39:101044. https://doi.org/10.1016/j.molmet.2020.101044
doi: 10.1016/j.molmet.2020.101044
pubmed: 32585364
pmcid: 7308743
Yen FS, Wei JCC, Shih YH, Hsu CC, Hwu CM (2022) Metformin use and the risk of bacterial pneumonia in patients with type 2 diabetes. Sci Rep 12(1):1–9. https://doi.org/10.1038/s41598-022-07294-1
doi: 10.1038/s41598-022-07294-1
Khateeb J, Fuchs E, Khamaisi M (2019) Diabetes and lung disease: an underestimated relationship. Rev Diabet Stud 15(1):1–15. https://doi.org/10.1900/RDS.2019.15.1
doi: 10.1900/RDS.2019.15.1
pubmed: 30489598
pmcid: 6760893
Lamers MM, Haagmans BL (2022) SARS-CoV-2 pathogenesis. Nat Rev Microbiol 20(5):270–284. https://doi.org/10.1038/s41579-022-00713-0
doi: 10.1038/s41579-022-00713-0
pubmed: 35354968
Al-Awwal N, Dweik F, Mahdi S, El-Dweik M, Anderson SH (2022) A review of SARS-CoV-2 disease (COVID-19): Pandemic in our time. Pathogens 11(3):1–14. https://doi.org/10.3390/pathogens11030368
doi: 10.3390/pathogens11030368
Jain V, Vashisht R, Yilmaz G, Bhardwaj A (2022) Pneumonia pathology. StatPearls, Treasure Island Florida, pp 1–10
Pahal P, Rajasurya V, Sharma S (2022) Typical bacterial pneumonia. StatPearls, Treasure Island Florida, pp 1–10
Gill CM, Dolan L, Piggott LM, McLaughlin AM (2022) New developments in tuberculosis diagnosis and treatment. Breathe 18(1):1–15. https://doi.org/10.1183/20734735.0149-2021
doi: 10.1183/20734735.0149-2021
Natarajan A, Beena PM, Devnikar AV, Mali S (2020) A systemic review on tuberculosis. Indian J Tuberc 67(3):295–311. https://doi.org/10.1016/j.ijtb.2020.02.005
doi: 10.1016/j.ijtb.2020.02.005
pubmed: 32825856
World Health Organization. (n.d.). Tuberculosis. https://www.who.int/news-room/fact-sheets/detail/tuberculosis . Accessed 10 May 2023
World Health Organization. (n.d.). Tuberculosis deaths and disease increase during the COVID-19 pandemic. https://www.who.int/news/item/27-10-2022-tuberculosis-deaths-and-disease-increase-during-the-covid-19-pandemic . Accessed 10 May 2023
World Health Organization. (n.d.) TB incidence. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023/tb-disease-burden/1-1-tb-incidence . Accessed 1 Apr 2024
Guirado E, Schlesinger LS, Kaplan G (2013) Macrophages in tuberculosis: friend or foe. Semin Immunopathol 35(5):563–583. https://doi.org/10.1007/s00281-013-0388-2
doi: 10.1007/s00281-013-0388-2
pubmed: 23864058
pmcid: 3763202
Abdi A, Jalilian M, Sarbarzeh PA, Vlaisavljevic Z (2020) Diabetes and COVID-19: a systematic review on the current evidences. Diabetes Res Clin Pract 166(108347):1–14. https://doi.org/10.1016/j.diabres.2020.108347
doi: 10.1016/j.diabres.2020.108347
Lowenstein CJ, Solomon SD (2020) Severe COVID-19 is a microvascular disease. Circulation 142(17):1609–1611. https://doi.org/10.1161/CIRCULATIONAHA.120.050354
doi: 10.1161/CIRCULATIONAHA.120.050354
pubmed: 32877231
pmcid: 7580651
Singh AK, Gupta R, Ghosh A, Misra A (2020) Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr 14(4):303–310. https://doi.org/10.1016/j.dsx.2020.04.004
doi: 10.1016/j.dsx.2020.04.004
pubmed: 32298981
pmcid: 7195120
Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y (2020) Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 94:91–95. https://doi.org/10.1016/j.ijid.2020.03.017
doi: 10.1016/j.ijid.2020.03.017
pubmed: 32173574
pmcid: 7194638
Onder G, Rezza G, Brusaferro S (2020) Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 323(18):1775–1776. https://doi.org/10.1001/jama.2020.4683
doi: 10.1001/jama.2020.4683
pubmed: 32203977
Bhatraju PK, Ghassemieh BJ, Nichols M et al (2020) Covid-19 in critically ill patients in the seattle region—case series. N Engl J Med 382(21):2012–2022. https://doi.org/10.1056/NEJMoa2004500
doi: 10.1056/NEJMoa2004500
pubmed: 32227758
Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, Sun GZ, Yang GR, Zhang XL, Wang L, Xu X, Xu XP, Chan JCN (2006) Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med 23(6):623–628. https://doi.org/10.1111/j.1464-5491.2006.01861.x
doi: 10.1111/j.1464-5491.2006.01861.x
pubmed: 16759303
Pinedo-Torres I, Flores-Fernández M, Yovera-Aldana M, Gutierrez-Ortiz C, Zegarra-Lizana P, Intimayta-Escalante C, Moran-Mariños C, Alva-Diaz C, Pacheco-Barrios K (2020) Prevalence of diabetes mellitus and its associated unfavorable outcomes in patients with acute respiratory syndromes due to coronaviruses infection: a systematic review and meta-analysis. Clin Med Insights Endocrinol Diabetes 13:1–16. https://doi.org/10.1177/1179551420962495
doi: 10.1177/1179551420962495
Antonio-Arques V, Franch-Nadal J, Caylà JA (2021) Diabetes and tuberculosis: a syndemic complicated by COVID-19. Med Clin (Barc) 157(6):288–293. https://doi.org/10.1016/j.medcle.2021.04.006
doi: 10.1016/j.medcle.2021.04.006
pubmed: 34541325
Kansal HM, Srivastava S, Bhargava SK (2021) Diabetes mellitus and tuberculosis. J Int Med Sci 28(1):58–60
Lim K, McShane L, Rees M, Muhi S (2021) Cerebral melioidosis in an immunocompromised traveller: an argument for prevention. J Travel Med 28(1):1–3. https://doi.org/10.1093/jtm/taaa187
doi: 10.1093/jtm/taaa187
Nassar M, Daoud A, Nso N, Medina L, Ghernautan V, Bhangoo H, Nyein A, Mohamed M, Alqassieh A, Soliman K, Alfishawy M, Sachmechi I, Misra A (2021) Diabetes mellitus and covid-19: review article. Diabetes Metab Syndr 15(6):1–8. https://doi.org/10.1016/j.dsx.2021.102268
doi: 10.1016/j.dsx.2021.102268
Sen S, Chakraborty R, Kalita P, Pathak MP (2021) Diabetes mellitus and COVID-19: understanding the association in light of current evidence. World J Clin Cases 9(28):8327–8339. https://doi.org/10.12998/2Fwjcc.v9.i28.8327
doi: 10.12998/2Fwjcc.v9.i28.8327
pubmed: 34754842
pmcid: 8554438
Brufsky A (2020) Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic. J Med Virol 92(7):770–775. https://doi.org/10.1002/jmv.25887
doi: 10.1002/jmv.25887
pubmed: 32293710
pmcid: 7262330
Singh AK, Gupta R, Misra A (2020) Comorbidities in COVID-19: outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr 14(4):283–287. https://doi.org/10.1016/j.dsx.2020.03.016
doi: 10.1016/j.dsx.2020.03.016
pubmed: 32283499
pmcid: 7144598
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q (2020) Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 130(5):2620–2629. https://doi.org/10.1172/jci137244
doi: 10.1172/jci137244
pubmed: 32217835
pmcid: 7190990
Notarbartolo S, Ranzani V, Bandera A, Gruarin P, Bevilacqua V, Putignano AR, Gobbini A, Galeota E, Manara C, Bombaci M, Pesce E, Zagato E et al (2021) Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients. Sci Immunol 6(62):eabg5021. https://doi.org/10.1126/sciimmunol.abg5021
doi: 10.1126/sciimmunol.abg5021
pubmed: 34376481
Su Y, Chen D, Yuan D, Lausted C, Choi J, Dai CL, Voillet V, Duvvuri VR, Scherler K, Troisch P, Baloni P, Qin G, Smith B, Kornilov SA et al (2020) Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19. Cell 183(6):1479–1495. https://doi.org/10.1016/j.cell.2020.10.037
doi: 10.1016/j.cell.2020.10.037
pubmed: 33171100
pmcid: 7598382
Gao F, Mallajosyula V, Arunachalam PS, Ploeg KVD, Manohar M, Roltgen K, Yang F, Wirz O, Hoh R et al (2023) Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8+ T cell responses post SARS-CoV-2 infection. Immunity 56(4):864–878. https://doi.org/10.1016/j.immuni.2023.03.005
doi: 10.1016/j.immuni.2023.03.005
pubmed: 36996809
pmcid: 10017386
Yu KK, Fischinger S, Smith MT, Atyeo C, Cizmeci D, Wolf CR, Layton ED, Logue JK, Aguilar MS, Shuey L, Loos C, Yu J et al (2021) Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2. JCI Insight 6(6):e146242. https://doi.org/10.1172/jci.insight.146242
doi: 10.1172/jci.insight.146242
pubmed: 33621211
pmcid: 8026190
Tong ZWM, Grant E, Gras S, Wu M, Smith C, Barrett HL, Gallo LA, Short KR (2021) The role of T-cell immunity in COVID-19 severity amongst people living with type II diabetes. FEBS J 288(17):5042–5054. https://doi.org/10.1111/febs.16105
doi: 10.1111/febs.16105
pubmed: 34216102
pmcid: 8420365
Han M, Ma K, Wang X, Yan W, Wang H, You J, Wang Q, Chen H, Guo W, Chen T, Ning Q, Luo X (2021) Immunological characteristics in type 2 diabetes mellitus among COVID-19 patients. Front Endocrinol (Lausanne) 12:596518. https://doi.org/10.3389/fendo.2021.596518
doi: 10.3389/fendo.2021.596518
pubmed: 33776910
Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP (2020) The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 20(6):363–374. https://doi.org/10.1038/s41577-020-0311-8
doi: 10.1038/s41577-020-0311-8
pubmed: 32346093
pmcid: 7187672
Restrepo BI (2016) Diabetes and tuberculosis. Microbiol Spectr 4(6):1–11. https://doi.org/10.1128/microbiolspec.tnmi7-0023-2016
doi: 10.1128/microbiolspec.tnmi7-0023-2016
Gomez DI, Twahirwa M, Schlesinger LS, Restrepo BI (2013) Reduced association of mycobacteria with monocytes from diabetes patients with poor glucose control. Tuberculosis (Edinb) 93(2):192–197. https://doi.org/10.1016/j.tube.2012.10.003
doi: 10.1016/j.tube.2012.10.003
pubmed: 23131496
Restrepo BI, Twahirwa M, Rahbar MH, Schlesinger LS (2014) Phagocytosis via complement or Fc-gamma receptors is compromised in monocytes from type 2 diabetes patients with chronic hyperglycemia. PLoS ONE 9(3):1–8. https://doi.org/10.1371/journal.pone.0092977
doi: 10.1371/journal.pone.0092977
Chakravorty A, Heath CH (2019) Melioidosis: an updated review. Aust J Gen Pract 48(5):327–332. https://doi.org/10.31128/ajgp-04-18-4558
doi: 10.31128/ajgp-04-18-4558
pubmed: 31129946
Hii SYF, Tandhavanant S, Phunpang R, Ekchariyawat P, Saiprom N, Chewapreecha C, Seng R, Thiansukhon E, Morakot C, Sangsa N, Chayangsu S, Chuananont S, Tanwisaid K, Silakun W, Buasi N, Chaisuksant S, Hompleum T, Chetchotisakd P, Day NPJ, Chantratita W, Lertmemongkolchai G, West TE, Chantratita N (2021) Antibiotic susceptibility of clinical Burkholderia pseudomallei isolates in northeast Thailand from 2015 to 2018 and the genomic characterization of β-lactam-resistant isolates. Antimicrob Agents Chemother 65(5):1–19. https://doi.org/10.1128/AAC.02230-20
doi: 10.1128/AAC.02230-20
Selvam K, Ganapathy T, Najib MA, Khalid MF, Abdullah NA, Harun A, Wan Mohammad WMZ, Aziah I (2022) Burden and risk factors of melioidosis in Southeast Asia: a scoping review. Int J Environ Res Public Health 19(23):1–16. https://doi.org/10.3390/ijerph192315475
doi: 10.3390/ijerph192315475
Cheng AC, Currie BJ (2005) Melioidosis: epidemiology, pathophysiology, and management. Clin Miceobiol Rev 18(2):383–416. https://doi.org/10.1128/cmr.18.2.383-416.2005
doi: 10.1128/cmr.18.2.383-416.2005
Roe C, Vazquez AJ, Phillips PD, Allender CJ, Bowen RA, Nottingham RD, Doyle A, Wongsuwan G, Wuthiekanun V, Limmathurotsakul D, Peacock S, Keim P, Tuanyok A, Wagner DM, Sahl JW (2022) Multiple phylogenetically-diverse, differentially-virulent Burkholderia pseudomallei isolated from a single soil sample collected in Thailand. PLoS Negl Trop Dis 16(2):1–21. https://doi.org/10.1371/journal.pntd.0010172
doi: 10.1371/journal.pntd.0010172
Stone JK, DeShazer D, Brett PJ, Burtnick MN (2014) Melioidosis: molecular aspects of pathogenesis. Expert Rev Anti Infect Ther 12(12):1487–1499. https://doi.org/10.1586/14787210.2014.970634
doi: 10.1586/14787210.2014.970634
pubmed: 25312349
pmcid: 4409121
Yip CH, Ghazali AK, Nathan S (2020) Burkholderia pseudomallei pathogenesis and survival in different niches. Biochem Soc Trans 48(2):569–579. https://doi.org/10.1042/BST20190836
doi: 10.1042/BST20190836
pubmed: 32167134
Lara-Tejero M, Galán JE (2019) The injectisome, a complex nanomachine for protein injection into mammalian cells. EcoSal Plus 8(2):1–12. https://doi.org/10.1128/ecosalplus.esp-0039-2018
doi: 10.1128/ecosalplus.esp-0039-2018
Lombardi C, Tolchard J, Bouillot S, Signor L, Gebus C, Liebl D, Fenel D, Teulon JM, Brock J, Habenstein B, Pellequer JL, Faudry E, Loquet A, Attrée I, Dessen A, Job V (2019) Structural and functional characterization of the type three secretion system (T3SS) needle of pseudomonas aeruginosa. Front Microbiol 10:1–15. https://doi.org/10.3389/fmicb.2019.00573
doi: 10.3389/fmicb.2019.00573
Heacock-Kang Y, McMillan IA, Norris MH, Sun Z, Zarzycki-Siek J, Bluhm AP, Cabanas D, Norton RE, Ketheesan N, Miller JF, Schweizer HP, Hoang TT (2021) The Burkholderia pseudomallei intracellular ‘TRANSITome.’ Nat Commun 12(1):1–12. https://doi.org/10.1038/s41467-021-22169-1
doi: 10.1038/s41467-021-22169-1
Chuaygud T, Tungpradabkul S, Sirisinha S, Chua KL, Utaisincharoen P (2008) A role of Burkholderia pseudomallei flagella as a virulent factor. Trans R Soc Trop Med Hyg 102(1):140–144. https://doi.org/10.1016/s0035-9203(08)70031-2
doi: 10.1016/s0035-9203(08)70031-2
Burtnick MN, Brett PJ, Harding SV, Ngugi SA, Ribot WJ, Chantratita N, Scorpio A, Milne TS, Dean RE, Fritz DL, Peacock SJ, Prior JL, Atkins TP, DeShazer D (2011) The cluster 1 type VI secretion system is a major virulence determinant in Burkholderia pseudomallei. Infect Immun 79(4):1512–1525. https://doi.org/10.1128/iai.01218-10
doi: 10.1128/iai.01218-10
pubmed: 21300775
pmcid: 3067527
Chin CY, Monack DM, Nathan S (2010) Genome wide transcriptome profiling of a murine acute melioidosis model reveals new insights into how Burkholderia pseudomallei overcomes host innate immunity. BMC Genomics 11(1):1–14. https://doi.org/10.1186/1471-2164-11-672
doi: 10.1186/1471-2164-11-672
Ghazali AK, Firdaus-Raih M, Uthaya Kumar A, Lee WK, Hoh CC, Nathan S (2023) Transitioning from soil to host: comparative transcriptome analysis reveals the Burkholderia pseudomallei response to different niches. Microbiol spectr 11(2):1–21. https://doi.org/10.1128/spectrum.03835-22
doi: 10.1128/spectrum.03835-22
Wiersinga WJ, Virk HS, Torres AG, Currie BJ, Peacock SJ, Dance DAB, Limmathurotsakul D (2018) Melioidosis. Nat Rev Dis Primers 4(1):1–22. https://doi.org/10.1038/nrdp.2017.107
doi: 10.1038/nrdp.2017.107
Chowdhury S, Barai L, Afroze SR, Ghosh PK, Afroz F, Rahman H, Ghosh S, Hossain MB, Rahman MZ, Das P, Rahim MA (2022) The epidemiology of melioidosis and its association with diabetes mellitus: a systematic review and meta-analysis. Pathogens 11(2):1–15. https://doi.org/10.3390/pathogens11020149
doi: 10.3390/pathogens11020149
Chanchamroen S, Kewcharoenwong C, Susaengrat W, Ato M, Lertmemongkolchai G (2009) Human polymorphonuclear neutrophil responses to Burkholderia pseudomallei in healthy and diabetic subjects. Infect Immun 77(1):456–463. https://doi.org/10.1128/iai.00503-08
doi: 10.1128/iai.00503-08
pubmed: 18955471
Morris JL, Govan BL, Rush CM, Ketheesan N (2021) Identification of defective early immune responses to Burkholderia pseudomallei infection in a diet-induced murine model of type 2 diabetes. Microbes Infect 23(4–5):104793. https://doi.org/10.1016/j.micinf.2021.104793
doi: 10.1016/j.micinf.2021.104793
pubmed: 33571673
Buddhisa S, Rinchai D, Ato M, Bancroft GJ, Lertmemongkolchai G (2015) Programmed death ligand 1 on Burkholderia pseudomallei–infected human polymorphonuclear neutrophils impairs T cell functions. J Immun 194(9):4413–4421. https://doi.org/10.4049/jimmunol.1402417
doi: 10.4049/jimmunol.1402417
pubmed: 25801435
Kronsteiner B, Chaichana P, Sumonwiriya M, Jenjaroen K, Chowdhury F, Chumseng S, Teparrukkul P, Limmathurotsakul D, Day N, Klenerman P, Dunachie S (2019) Diabetes alters immune response patterns to acute melioidosis in humans. Eur J Immunol 49(7):1092–1106. https://doi.org/10.1002/eji.201848037
doi: 10.1002/eji.201848037
pubmed: 31032897
pmcid: 6618312
Jurado JO, Alvarez IB, Pasquinelli V, Martinez GJ, Quiroga MF, Abbate E, Musella RM, Chuluyan HE, Garcia VE (2008) Programmed death (PD)-1: PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol 181(1):116–125. https://doi.org/10.4049/jimmunol.181.1.116
doi: 10.4049/jimmunol.181.1.116
pubmed: 18566376
Tigner A, Ibrahim SA, Murray I (2022) Histology, white blood cell. StatPearls, Treasure Island Florida, pp 1–10
Barnes J, Williams N, Ketheesan N (2012) Susceptibility to Burkholderia pseudomallei is associated with diabetes mellitus and other risk factors. PLoS ONE 7(10):1–15. https://doi.org/10.1111/j.1574-695X.2008.00389.x
doi: 10.1111/j.1574-695X.2008.00389.x
Morris J, Williams N, Rush C, Govan B, Sangla K, Norton R, Ketheesan N (2012) Burkholderia pseudomallei triggers altered inflammatory profiles in a whole-blood model of type 2 diabetes-melioidosis comorbidity. Infect Immun 80(6):2089–2099. https://doi.org/10.1128/iai.00212-12
doi: 10.1128/iai.00212-12
pubmed: 22473609
pmcid: 3370601
Chin CY, Monack DM, Nathan S (2012) Delayed activation of host innate immune pathways in streptozotocin-induced diabetic hosts leads to more severe disease during infection with Burkholderia pseudomallei. Immunology 135(4):312–332. https://doi.org/10.1111/j.1365-2567.2011.03544.x
doi: 10.1111/j.1365-2567.2011.03544.x
pubmed: 22136109
pmcid: 3372747